Clinical rigor and bending the cost curve: Policies and process in the MassHealth Pharmacy Program
Today, healthcare policy experts at the Massachusetts Health Policy Forum (MHPF) presented findings from a new report on the development and impact of the MassHealth pharmacy program’s drug list.
The MHPF study, supported by Community Catalyst and the Pew Prescription Project, concludes that the Massachusetts model is a successful and clinically rigorous approach to bending the pharmaceutical cost curve. The authors noted that MassHealth saved at least $99 million in the MassHealth drug list’s first year, and the list, because of the process and involvement of stakeholders, was accepted by most providers with considerable success and faced limited resistance by advocates.
For more on the forum, visit the MHPF website.